Type 2 Diabetes

T2D management has been reshaped by GLP-1 and SGLT2 therapies with growing personalisation. The session covers the ADA-EASD 2025 consensus statement, time-in-range as a primary endpoint replacing HbA1c-only focus, once-weekly basal insulin (icodec ONWARDS-1-6, efsitora QWINT programme), CGM in T2D and Medicare expansion, the personalised treatment algorithm based on CKM phenotype, and T2D remission criteria. Discussion addresses GLP-1 as first-line in T2D plus obesity, SGLT2i across organ systems, finerenone integration in DKD, the cost-effectiveness landscape, T2D in adolescents (the rising epidemiology), and the implementation gap between guidelines and primary-care practice.